A new study conducted by researchers at the Mayo Clinic
shows that samarium-153 lexidronam (Quadramet), approved by the US Food and Drug
Administration (FDA) in 1997 for the treatment of pain in patients with
metastatic bone lesions, can be used at higher doses to treat osteosarcoma. The
results of the study were published recently in the Journal of Clinical Oncology
According to the study, 24 of 30 patients undergoing treatment with
samarium-153 lexidronam experienced good to excellent results in delaying local
progression of their disease. All patients in the study had failed two or more
previous therapies and had multiple sites of bone cancer. In two patients, the
cancer had been in complete remission for more than 2 years following treatment.
"Quadramet is an effective treatment option in helping to relieve the
pain often experienced by patients with metastatic bone cancer. We are very
encouraged by these early results that indicate Quadramet may also be useful in
the treatment of osteosarcoma," said H. Joseph Reiser, PhD, president and
CEO of Cytogen, manufacturer of the radiopharmaceutical agent.
Osteosarcoma occurs most often in teenagers and is twice as common in males
as in females. Standard treatment for osteosarcoma consists of surgery or
chemotherapy. "In some patients, surgery or chemotherapy cannot adequately
control osteosarcoma. These study results indicate that Quadramet could be a new
treatment option for patients who would otherwise have a poor prognosis,"
said Peter Anderson, MD, PhD, a pediatric oncologist at the Mayo Clinic.
Primary bone cancers commonly result in the formation of new bone regardless
of whether the tumor remains confined to the skeleton or has spread to soft
tissues such as the lung. Samarium-153 lexidronam targets these areas of new
bone formation, delivering site-specific radiation.